Screening of Isoflavone-Modified Compounds as Potential Therapeutic Agents towards Skin Inflammation Disease in Cellular Level

Abstract

inflammation plays a crucial role in the pathogenesis of various skin conditions such as psoriasis and atopic dermatitis, primarily driven by abnormal cytokine production. This study investigates the anti-inflammatory potential of several synthetic isoflavone-modified compounds (CYR-6811k, CYR-6812l, CYR-6813m, CYR-6815o, CYR-6816p) by examining their effects on cytokine production in THP-1 and HaCaT cells. The selected compounds were evaluated for their ability to inhibit the production of key cytokines, including IL-6, IL-8, TNF-α, and CXCL1. The results indicate that the synthetic isoflavone-modified compounds significantly inhibited IL-6 and IL-8 production in both cell lines, suggesting their potential as therapeutic agents for treating skin inflammatory diseases. However, their effects on TNF-α and CXCL1 production were less consistent. These findings underscore the complexity of cytokine modulation and the potential of isoflavone derivatives in dermatological therapeutics. Future research should focus on further optimization and testing of these compounds to enhance their efficacy and understand their broader implications. Recommendations include exploring a broader range of cytokines, investigating the specific pathways targeted by these compounds, and comparing their effectiveness with established anti-inflammatory drugs.